Identification and Evaluation of New Immunoregulatory Genes in Mesenchymal Stromal Cells of Different Origins: Comparison of Normal and Inflammatory Conditions
- PMID: 28336906
- PMCID: PMC5378277
- DOI: 10.12659/msmbr.903518
Identification and Evaluation of New Immunoregulatory Genes in Mesenchymal Stromal Cells of Different Origins: Comparison of Normal and Inflammatory Conditions
Abstract
BACKGROUND Mesenchymal stromal cells (MSCs) possess potent immunomodulatory properties that increase their value as a cell-based therapeutic tool for managing various immune-based disorders. Over the past years, accumulated results from trials using MSCs-based therapy have shown substantial contradictions. Although the reasons underlying these discrepancies are still not completely understood, it is well known that the immunomodulatory activities mediated by distinct MSCs differ in a manner dependent on their tissue origin and adequate response to inflammation priming. Thus, characterization of new molecular pathway(s) through which distinct MSC populations can exert their immunomodulatory effects, particularly during inflammation, will undoubtedly enhance their therapeutic potential. MATERIAL AND METHODS After confirming their compliance with ISCT criteria, quantitative real time-PCR (qRT-PCR) was used to screen new immunoregulatory genes in MSCs, derived from adipose tissue, foreskin, Wharton's jelly or the bone-marrow, after being cultivated under normal and inflammatory conditions. RESULTS FGL2, GAL, SEMA4D, SEMA7A, and IDO1 genes appeared to be differentially transcribed in the different MSC populations. Moreover, these genes were not similarly modulated following MSCs-exposure to inflammatory signals. CONCLUSIONS Our observations suggest that these identified immunoregulatory genes may be considered as potential candidates to be targeted in order to enhance the immunomodulatory properties of MSCs towards more efficient clinical use.
Figures

Similar articles
-
Comparative Analyses of Immunosuppressive Characteristics of Bone-Marrow, Wharton's Jelly, and Adipose Tissue-Derived Human Mesenchymal Stem Cells.Turk J Haematol. 2017 Aug 2;34(3):213-225. doi: 10.4274/tjh.2016.0171. Epub 2016 Sep 9. Turk J Haematol. 2017. PMID: 27610554 Free PMC article.
-
Differential expression of cell cycle and WNT pathway-related genes accounts for differences in the growth and differentiation potential of Wharton's jelly and bone marrow-derived mesenchymal stem cells.Stem Cell Res Ther. 2017 Apr 26;8(1):102. doi: 10.1186/s13287-017-0555-9. Stem Cell Res Ther. 2017. PMID: 28446235 Free PMC article.
-
The Comparison of Immunomodulatory Properties of Canine and Human Wharton Jelly-Derived Mesenchymal Stromal Cells.Int J Mol Sci. 2024 Aug 16;25(16):8926. doi: 10.3390/ijms25168926. Int J Mol Sci. 2024. PMID: 39201612 Free PMC article.
-
Characteristics and clinical applications of Wharton's jelly-derived mesenchymal stromal cells.Curr Res Transl Med. 2020 Jan;68(1):5-16. doi: 10.1016/j.retram.2019.09.001. Epub 2019 Sep 19. Curr Res Transl Med. 2020. PMID: 31543433 Review.
-
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases.Nat Rev Nephrol. 2018 Aug;14(8):493-507. doi: 10.1038/s41581-018-0023-5. Nat Rev Nephrol. 2018. PMID: 29895977 Review.
Cited by
-
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.Stem Cell Res Ther. 2019 May 2;10(1):131. doi: 10.1186/s13287-019-1224-y. Stem Cell Res Ther. 2019. PMID: 31046833 Free PMC article. Review.
-
Identification of Differentially Expressed lncRNAs and mRNAs in Children with Acquired Aplastic Anemia by RNA Sequencing.Biomed Res Int. 2020 Jun 28;2020:8962090. doi: 10.1155/2020/8962090. eCollection 2020. Biomed Res Int. 2020. PMID: 32685541 Free PMC article. Clinical Trial.
-
Factors Defining Human Adipose Stem/Stromal Cell Immunomodulation in Vitro.Stem Cell Rev Rep. 2024 Jan;20(1):175-205. doi: 10.1007/s12015-023-10654-7. Epub 2023 Nov 14. Stem Cell Rev Rep. 2024. PMID: 37962697 Free PMC article. Review.
-
Aldehyde dehydrogenase activity of Wharton jelly mesenchymal stromal cells: isolation and characterization.Cytotechnology. 2019 Feb;71(1):427-441. doi: 10.1007/s10616-018-0283-8. Epub 2019 Jan 4. Cytotechnology. 2019. PMID: 30610510 Free PMC article.
-
Therapeutic Mesenchymal Stem/Stromal Cells: Value, Challenges and Optimization.Front Cell Dev Biol. 2022 Jan 14;9:716853. doi: 10.3389/fcell.2021.716853. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35096805 Free PMC article. Review.
References
-
- Friedenstein AJ, Deriglasova UF, Kulagina NN, et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2:83–92. - PubMed
-
- Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–47. - PubMed
-
- Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42–48. - PubMed
-
- Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106:1755–61. - PubMed
-
- Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (London, England) 2004;363:1439–41. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous